Ono Pharmaceutical Co Ltd
TSE:4528

Watchlist Manager
Ono Pharmaceutical Co Ltd Logo
Ono Pharmaceutical Co Ltd
TSE:4528
Watchlist
Price: 1 606 JPY -0.12% Market Closed
Market Cap: 754.2B JPY
Have any thoughts about
Ono Pharmaceutical Co Ltd?
Write Note

Ono Pharmaceutical Co Ltd
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Ono Pharmaceutical Co Ltd
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Ono Pharmaceutical Co Ltd
TSE:4528
Total Equity
ÂĄ782.5B
CAGR 3-Years
5%
CAGR 5-Years
7%
CAGR 10-Years
6%
Takeda Pharmaceutical Co Ltd
TSE:4502
Total Equity
ÂĄ6.9T
CAGR 3-Years
9%
CAGR 5-Years
7%
CAGR 10-Years
11%
Daiichi Sankyo Co Ltd
TSE:4568
Total Equity
ÂĄ1.6T
CAGR 3-Years
7%
CAGR 5-Years
5%
CAGR 10-Years
5%
Otsuka Holdings Co Ltd
TSE:4578
Total Equity
ÂĄ2.5T
CAGR 3-Years
8%
CAGR 5-Years
8%
CAGR 10-Years
5%
Chugai Pharmaceutical Co Ltd
TSE:4519
Total Equity
ÂĄ1.6T
CAGR 3-Years
15%
CAGR 5-Years
15%
CAGR 10-Years
11%
Astellas Pharma Inc
TSE:4503
Total Equity
ÂĄ1.5T
CAGR 3-Years
3%
CAGR 5-Years
3%
CAGR 10-Years
2%
No Stocks Found

Ono Pharmaceutical Co Ltd
Glance View

Market Cap
754.4B JPY
Industry
Pharmaceuticals

In the bustling city of Osaka, Japan, Ono Pharmaceutical Co., Ltd. stands as a venerable institution with roots tracing back over three centuries. Origination in 1717 as an apothecary, Ono has evolved into a leading biopharmaceutical company renowned for its pioneering work in immunology. They have a rich history of innovation in drug development, marked by the success of their groundbreaking anti-cancer agent, Opdivo. This is a product of their intensive research and development in the field of immune checkpoint inhibitors, a class of drugs that revolutionizes cancer treatment by bolstering the body's natural defenses to combat malignant cells. Ono’s commitment to R&D, underscored by substantial investment, remains its cornerstone, transforming complex scientific concepts into therapeutic products. The essence of Ono Pharmaceutical’s business model rests on its adeptness at translating scientific excellence into commercial success. They operate within two primary segments: pharmaceutical products and clinical testing-related services. The pharmaceutical segment, the larger of the two, is the engine driving revenue through the development and global distribution of prescription drugs, focusing extensively on treatments in the central nervous system, cancer, and infectious diseases. Ono leverages strategic alliances with global pharmaceutical giants, facilitating broader distribution networks and shared research endeavors, thus amplifying their market presence and financial returns. Their strategy encapsulates a cycle of discovery, development, and commercialization, continually striving to deliver innovative medicinal solutions that enhance the quality of life worldwide.

Intrinsic Value
2 699.78 JPY
Undervaluation 41%
Intrinsic Value
Price

See Also

What is Ono Pharmaceutical Co Ltd's Total Equity?
Total Equity
782.5B JPY

Based on the financial report for Sep 30, 2024, Ono Pharmaceutical Co Ltd's Total Equity amounts to 782.5B JPY.

What is Ono Pharmaceutical Co Ltd's Total Equity growth rate?
Total Equity CAGR 10Y
6%

Over the last year, the Total Equity growth was 1%. The average annual Total Equity growth rates for Ono Pharmaceutical Co Ltd have been 5% over the past three years , 7% over the past five years , and 6% over the past ten years .

Back to Top